 | • レポートコード：MRC2303K022 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、年度末に599百万ドルであった世界のヒトマイクロバイオーム市場規模が、予測期間中、CAGR 15.04％で増大すると予測されています。本レポートでは、ヒトマイクロバイオームの世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、用途別（治療、診断）分析、疾患別（肥満、糖尿病、自己免疫疾患、がん、その他）分析、疾患別（肥満、糖尿病、自己免疫疾患、がん、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、AOBiome 、Astarte Medical、Axial Biotherapeutics, Inc.、DuPont、Enterome 、Evelo Biosciences Inc、Finch Therapeutics Group Inc.、Ginkgo Bioworks、Exeliom Biosciences SAS、Osel Inc.、Second Genome Inc.、Seres Therapeuticsなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のヒトマイクロバイオーム市場規模：用途別 - 治療における市場規模 - 診断における市場規模 ・世界のヒトマイクロバイオーム市場規模：疾患別 - 肥満における市場規模 - 糖尿病における市場規模 - 自己免疫疾患における市場規模 - がんにおける市場規模 - その他疾患における市場規模 ・世界のヒトマイクロバイオーム市場規模：製品別 - プロバイオティクスの市場規模 - プレバイオティクスの市場規模 - シンバイオティクスの市場規模 - その他ヒトマイクロバイオームの市場規模 ・世界のヒトマイクロバイオーム市場規模：地域別 - 北米のヒトマイクロバイオーム市場規模 アメリカのヒトマイクロバイオーム市場規模 カナダのヒトマイクロバイオーム市場規模 メキシコのヒトマイクロバイオーム市場規模 … - ヨーロッパのヒトマイクロバイオーム市場規模 ドイツのヒトマイクロバイオーム市場規模 イギリスのヒトマイクロバイオーム市場規模 フランスのヒトマイクロバイオーム市場規模 … - アジア太平洋のヒトマイクロバイオーム市場規模 中国のヒトマイクロバイオーム市場規模 日本のヒトマイクロバイオーム市場規模 インドのヒトマイクロバイオーム市場規模 … - 南米/中東のヒトマイクロバイオーム市場規模 南アフリカのヒトマイクロバイオーム市場規模 ブラジルのヒトマイクロバイオーム市場規模 アルゼンチンのヒトマイクロバイオーム市場規模 … ・競争状況 ・市場機会・将来動向 |
The human microbiome market is valued at USD 599 million in the current year and is expected to witness a CAGR of 15.04% during the forecast period.
The human microbiome has become an area of interest in recent times because of its association with several respiratory diseases and immunity. The gut microbiome has been known to be associated with good immunity. Researchers have reported that variation in the number of microorganisms, such as actinobacteria, firmicute, and Bacteroidetes, leads to the development of lung, respiratory and other disorders. For instance, in April 2020, Persephone Biosciences Inc. started developing an immune-boosting microbiome therapeutic to help prevent and fight the novel coronavirus (SARS-CoV-2) and a potential stool-based diagnostic test designed to help predict which patients are at the highest risk for developing severe complications and mortality after suffering COVID-19. Thus, increasing research studies on the microbiome are the key drivers affirming the growth of this market. The pandemic has created awareness about microbiota therapeutics and diagnosis; thus, the market is expected to follow the same trend even during the post-pandemic period.
Other key factors propelling the growth of this market are the increasing burden of lifestyle-related diseases and the growing geriatric population. For instance, as per the International Diabetes Federation 2021, statistics, there are 52.7 million people aged 20-79 years in Europe having diabetes, and this number is expected to reach 69 million by the year 2045. Increased gut microbial diversity, along with specifically more butyrate-producing bacteria, benefitting insulin resistance and risk of type 2 diabetes, increases the burden of lifestyle diseases such as diabetes, and is expected to drive the growth of the market over the forecast period.
Increasing funding initiatives and government programs to support this research are high-impact rendering drivers anticipated to foster market growth. For instance, as per the National Institute of Health, in May 2022, the Federal Government of the United States incurred USD 864 million on research and development of the microbiome in 2021 and is expected to spend USD 903 million in 2022. Such investment by the government is propelling the growth of the market over the forecast period. However, a lack of comprehensive research and stringent government regulations are likely to limit the market growth over the forecast period.
Human Microbiome Market Trends
Therapeutic Applications Expected to Hold the Considerable Share in the Studied Market Over the Forecast Period
Microbiome therapeutics found a broad range of applications in COVID-19, Inflammatory Bowel Disease (IBD), C. difficile infections, Crohn’s disease, and diabetes. The factors, such as rising research activities undertaken by research institutes and market players for finding more therapeutic applications of the human microbiome, coupled with the rising burden of diseases, are contributing to the market segment’s growth.
The increasing research studies are expected to boost the market segment’s growth. For instance, as per clinical trials. gov, the University of Zurich investigated the microbiota in COVID-19 patients for future preventive and therapeutic approaches (MICRO-COV). The study was started in April 2020 and is expected to be completed by December 2023. The positive results from such studies could lead to the development of new products and thus may drive the market segment’s growth in the future.
Additionally, an article published in Frontiers in Microbiology Journal in June 2021 reported that human gastrointestinal microbiome research could deliver critical clinical and therapeutic development if it shifts toward mechanistic studies. It also suggested that the development of more efficacious and targeted treatments relies on identifying causal links between the microbiome and disease, with future progress dependent on effective links between state-of-the-art sequencing approaches, computational analyses, and experimental assays. Such studies drive the growth of the market.
The agreements and collaborations also boost market segment growth among the market players to strengthen their position in the market. For instance, in July 2021, Seres Therapeutics Inc. entered into an agreement with Nestlé Health Science to jointly commercialize SER-109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI) in the United States and Canada. This investigational microbiome therapeutics may lead the way for an entirely new treatment modality.
North America Dominates the Market and Expected to do the Same Over the Forecast Period
North America currently dominates the market for the human microbiome due to the rising incidences of lifestyle-related diseases and autoimmune disorders in these regions coupled with a strong drug pipeline can also be attributed to the highly lucrative growth.
The growing burden of diseases in the region is also boosting the growth of the market. For instance, according to the American Cancer Society, 2022 estimates, there are about 1,918,030 new cases of cancer will be reported in the United States in 2022. Also, according to the Globocan 2020 statistics, there are 274,364 new cases of cancer and is expected to reach 400,564 new cases by 2040. Thus, such an increasing burden of cancer is expected to drive the growth of the market as gut microbiota play a regulatory role in tumor therapy including enhancing the sensitivity of patients to immunotherapy and reducing side effects of chemotherapeutic agents.
Additionally, the increasing research studies and support by the regulatory authorities for the investigation are also contributing to the growth of the market in the region. For instance, in February 2022, 4D pharma plc received FDA clearance for investigational new drug (IND) applications for two Live Biotherapeutics namely MRx0005 and MRx0029, for the treatment of Parkinson’s disease. Such approvals are expected to drive the growth of the market.
Thus, owing to the abovementioned factors, the studied market in the North America region is expected to project significant growth over the forecast period.
Human Microbiome Market Competitor Analysis
The human microbiome market is moderately competitive, and several players are coming up with new products. Companies like Axial Biotherapeutics, Inc, DuPont, Series Therapeutics, Second Genome, and Synthetic Biologics hold substantial shares in the market. Key players are focusing on enhancing the therapeutics pipeline by developing efficient and safe drugs.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidence of Lifestyle-related Diseases
4.2.2 Growing Geriatric Population
4.3 Market Restraints
4.3.1 Lack of Comprehensive Research
4.3.2 Stringent Government Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Application
5.1.1 Therapeutics
5.1.2 Diagnostics
5.2 By Disease
5.2.1 Obesity
5.2.2 Diabetes
5.2.3 Autoimmune Disorders
5.2.4 Cancer
5.2.5 Gastrointestinal Disorders
5.2.6 Central Nervous System Disorders
5.2.7 Other Diseases
5.3 By Product
5.3.1 Probiotics
5.3.2 Prebiotics
5.3.3 Symboitics
5.3.4 Other Products
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 AOBiome
6.1.2 Astarte Medical
6.1.3 Axial Biotherapeutics, Inc.
6.1.4 DuPont
6.1.5 Enterome
6.1.6 Evelo Biosciences Inc
6.1.7 Finch Therapeutics Group Inc.
6.1.8 Ginkgo Bioworks
6.1.9 Exeliom Biosciences SAS
6.1.10 Osel Inc.
6.1.11 Second Genome Inc.
6.1.12 Seres Therapeutics
7 MARKET OPPORTUNITIES AND FUTURE TRENDS